Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U3355
Biopharmaceutical Contract Manufacturing Market is estimated to value over CAGR of over 5.5% during the forecast period 2022 to 2028 With the increasing expansion of the biopharmaceutical industry, many manufacturers are facing multiple problems like dearth of expertise and systematic equipment during in-house manufacturing. The availability of external funding and biotech manufacturing has led to a spurt of bio companies in early stage as they are the primary CMO customers due to their lack of capability of developing vigorous manufacturing operations. Multiple established CMOs like Lonza and Boehringer Ingelheim have received competition from many emerging CMOs in this high-volume market. For example, Samsung entered this market as Samsung Biologics in 2013 and has since expanded their bioreactor capacities to witness growth in this sector. The company currently owns three plants with over 360,000 litres of capacity and the fourth plant is under assessment, which shall be located outside South Korea. Additionally, technological breakthroughs in bioprocessing have been crucial in the development of CMOs by working on issues like need of a batch-wise changeover and high production costs. Bioprocessing systems that can use once have proven to be significant in reducing the total scale-up and production costs. With strategic acquisitions and mergers, the biopharmaceutical contract manufacturing market growth is expected to grow substantially over the forecasted timeframe. However, established companies consider outsourcing as unfeasible owing to limited management oversight and loss of strategic control, resulting in these companies choosing in-house manufacturing operations. Market Segmentation: By Source • Mammalian Source • Non-Mammalian Source By Product • Biosimilars • Biologics o Monoclonal antibodies (MABs) o Recombinant Proteins o Vaccines o Antisense, RNAi, & Molecular Therapy o Others By Services • Product Development o Downstream o Upstream • Fill and Finish Operations • Analytical and QC Testing • Packaging By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is categorised into source, product, services and region. The source segment is diversified into mammalian source and mon-mammalian source. The mammalian contract manufacturing segment is anticipated to hold the largest biopharmaceutical contract manufacturing market share, and this can be credited to increased acceptance rate of mammalian system for producing biologics. Furthermore, most of the biopharma products currently in the pipeline are expressed by mammalian source. Companies like Charles River and Lonza have heavily invested in expanding their manufacturing facilities of mammalian cell culture for biosimilars and biologics. The product segment is classified into biosimilars and biologics. The biologics segment dominated the market in 2018 and this primarily owing to the massive commercial acceptance of biologics by the market. The service segment is fragmented into process development, fill and finish operations, analytical and QC testing and packaging. Regional Analysis: The North America region subjugated the market in 2017 owing to a strong presence of biopharma facilities in the Unites States along with increased research and development activities in biopharma sector. The Asia Pacific region, however, shall grow at a significant rate during the forecast period and this is due to low operating and manufacturing costs provided by countries like India. Competitive Landscape: The major market players associated are • Boehringer Ingelheim GmbH • Lonza • Inno Biologics Sdn Bhd • Rentschler Biotechnologie GmbH • JRS Pharma • AGC Biologics • ProBioGen • Fujifilm Diosynth Biotechnologies U.S.A., Inc. • Toyobo Co., Ltd. • Samsung BioLogics • Thermo Fisher Scientific, Inc. • Binex Co., Ltd. • WuXi Biologics • AbbVie, Inc. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global biopharmaceutical contract manufacturing market by source, by product, by services and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
With the increasing expansion of the biopharmaceutical industry, many manufacturers are facing multiple problems like dearth of expertise and systematic equipment during in-house manufacturing. The availability of external funding and biotech manufacturing has led to a spurt of bio companies in early stage as they are the primary CMO customers due to their lack of capability of developing vigorous manufacturing operations. Multiple established CMOs like Lonza and Boehringer Ingelheim have received competition from many emerging CMOs in this high-volume market. For example, Samsung entered this market as Samsung Biologics in 2013 and has since expanded their bioreactor capacities to witness growth in this sector. The company currently owns three plants with over 360,000 litres of capacity and the fourth plant is under assessment, which shall be located outside South Korea. Additionally, technological breakthroughs in bioprocessing have been crucial in the development of CMOs by working on issues like need of a batch-wise changeover and high production costs. Bioprocessing systems that can use once have proven to be significant in reducing the total scale-up and production costs. With strategic acquisitions and mergers, the biopharmaceutical contract manufacturing market growth is expected to grow substantially over the forecasted timeframe. However, established companies consider outsourcing as unfeasible owing to limited management oversight and loss of strategic control, resulting in these companies choosing in-house manufacturing operations.
Market Segmentation:
By Source • Mammalian Source • Non-Mammalian Source By Product • Biosimilars • Biologics o Monoclonal antibodies (MABs) o Recombinant Proteins o Vaccines o Antisense, RNAi, & Molecular Therapy o Others By Services • Product Development o Downstream o Upstream • Fill and Finish Operations • Analytical and QC Testing • Packaging By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is categorised into source, product, services and region. The source segment is diversified into mammalian source and mon-mammalian source. The mammalian contract manufacturing segment is anticipated to hold the largest biopharmaceutical contract manufacturing market share, and this can be credited to increased acceptance rate of mammalian system for producing biologics. Furthermore, most of the biopharma products currently in the pipeline are expressed by mammalian source. Companies like Charles River and Lonza have heavily invested in expanding their manufacturing facilities of mammalian cell culture for biosimilars and biologics. The product segment is classified into biosimilars and biologics. The biologics segment dominated the market in 2018 and this primarily owing to the massive commercial acceptance of biologics by the market. The service segment is fragmented into process development, fill and finish operations, analytical and QC testing and packaging.
Regional Analysis:
The North America region subjugated the market in 2017 owing to a strong presence of biopharma facilities in the Unites States along with increased research and development activities in biopharma sector. The Asia Pacific region, however, shall grow at a significant rate during the forecast period and this is due to low operating and manufacturing costs provided by countries like India.
Competitive Landscape:
The major market players associated are • Boehringer Ingelheim GmbH • Lonza • Inno Biologics Sdn Bhd • Rentschler Biotechnologie GmbH • JRS Pharma • AGC Biologics • ProBioGen • Fujifilm Diosynth Biotechnologies U.S.A., Inc. • Toyobo Co., Ltd. • Samsung BioLogics • Thermo Fisher Scientific, Inc. • Binex Co., Ltd. • WuXi Biologics • AbbVie, Inc.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global biopharmaceutical contract manufacturing market by source, by product, by services and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Biopharmaceutical Contract Manufacturing Market, By Source Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 7.1 Mammalian Source 7.2 Non-Mammalian Source 8. Biopharmaceutical Contract Manufacturing Market, By Product Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 8.1 Biosimilars 8.2 Biologics 8.2.1 Monoclonal antibodies (MABs) 8.2.2 Recombinant Proteins 8.2.3 Vaccines 8.2.4 Antisense, RNAi, & Molecular Therapy 8.2.5 Others 9. Biopharmaceutical Contract Manufacturing Market, By Services Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 9.1 Product Development 9.1.1 Downstream 9.1.2 Upstream 9.2 Fill and Finish Operations 9.3 Analytical and QC Testing 9.4 Packaging 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2016-2020 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4. Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for North America 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for North America 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 14.2.1 GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2022-2028 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 Boehringer Ingelheim GmbH 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 Lonza 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 Inno Biologics Sdn Bhd 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 Rentschler Biotechnologie GmbH 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 JRS PHARMA 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 AGC Biologics 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 ProBioGen 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Fujifilm Diosynth Biotechnologies U.S.A. Inc. 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Toyobo Co., Ltd. 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10 Samsung BioLogics 15.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11 Thermo Fisher Scientific Inc. 15.11.1. Company Overview (HQ, Business Segments, Employee Strength) 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 15.12 Binex Co. Ltd. 15.12.1. Company Overview (HQ, Business Segments, Employee Strength) 15.12.2. Product Portfolio 15.12.3. SWOT Analysis 15.12.4. Financial Overview 15.12.5. Strategic Overview 15.13 WuXi Biologics 15.13.1. Company Overview (HQ, Business Segments, Employee Strength) 15.13.2. Product Portfolio 15.13.3. SWOT Analysis 15.13.4. Financial Overview 15.13.5. Strategic Overview 15.14 AbbVie Inc. 15.14.1. Company Overview (HQ, Business Segments, Employee Strength) 15.14.2. Product Portfolio 15.14.3. SWOT Analysis 15.14.4. Financial Overview 15.14.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix 18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies 19. Relevant Case Studies and Latest News Updates 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics